Pasar al contenido principal

Investigación y educación

Enviado por remote_content el

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Transl Oncol.

Investigación y Educación

Background The KRAS exon 2 p. G12C mutation in patients with lung adenocarcinoma has been increasing in relevance due to the development and effectiveness of new treatment medications. Studies around different populations indicate that regional variability between ethnic groups and ancestries could play an essential role in developing this molecular alteration within lung cancer.

Conclusions Widespread identification of KRAS exon 2 p.G12C mutations, especially in cases where NGS is not easily achieved is feasible at a population based level that can characterize regional and national patterns of mutation status. Furthermore, this type of mutation prevalence follows a population substructure pattern that can be easily determined by population and ancestral markers such as STR.

Read full article

Artículos que te pueden interesar

Oncología

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab. Front Oncol.

Enero 5, 2022

Leer más

Oncología

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus). Thorac Cancer.

Marzo 17, 2021

Leer más

Oncología

Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non- Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. Oncology.

Abril 26, 2021

Leer más